Dr Camille Guillerey


Senior Research Officer

My Research

I am interested in blood cancers. These cancers include Lymphoma, Leukemia and Multiple Myeloma. I study how immune cells respond to these cancers and how we can harness this immune response to design better treatments for cancer patients.


PhD. Immune regulation through bi-directional interactions between subsets of Natural Killer cells and Dendritic cells.

PhD position 


This project will investigate interactions between two immune cell types: natural killer (NK) cells and dendritic cells (DCs). NK cells play an essential role in the early detection of infections or malignant transformation while DCs initiate and direct immune responses. Evidence for bi-directional interactions between NK cells and DCs has been provided in the early 2000s. Since then, our knowledge of NK cell and DC diversity has considerably increased. NK cells and DCs can no longer be considered as homogenous populations up to 30,000 phenotypic populations identified by mass cytometry in one individual [1] while four main human DC subsets have been described:  monocyte-derived DCs, plasmacytoid DCs and type 1 and 2 conventional DCs [2]. Currently, we don’t know which NK subset(s) interact with which DC subset(s).

This project aims to provide a better understanding of the crosstalk between distinct NK cell and DC subsets. Specific interactions between human cell subsets in response to different stimuli will be investigated in vitro and in vivo. The candidate will have access to state-of-the-art technology including high-parameter flow cytometry (BD Fortessa and BD FACSymphony analysers) as well as cutting-edge humanised mouse models [3, 4]. By addressing an important knowledge gap in the field, this project will lay the foundation for preclinical research in a wide range of pathologies including cancer, infectious diseases and autoimmune disorders.


The candidate will be enrolled in the PhD program at the University of Queensland and will receive a UQ PhD Scholarship. Stipend is valued at $28k per annum for 3 years.




The project will be performed in the Cancer Immunotherapies laboratory at Mater Research, located at the Translational Research Institute in Brisbane. https://www.materresearch.org.au/Our-research/Research-programs/Research-Group?group=117

Our laboratory is composed of 3 postdoctoral fellows, 1 research assistant and 1 PhD student. You will be directly supervised by Dr Camille Guillerey. 

We have extensive expertise in dendritic cell research [3-6] and NK cell research [7-10]. In addition, we have developed a unique preclinical model called humanised mice which allow the study of human immune cell interactions in vivo [3, 4]. Our group has an interest in cancer immunotherapies, and more particularly childhood leukaemia. We aim to provide a better understanding of immune responses to cancer and to translate it into new therapies for cancer patients.  


Please note that due to current travel restrictions, we will only accept candidates (Australian and international) who are currently in Australia.

Applicants must hold a Bachelor’s or equivalent science or medicine degree with first-class Honours, and/or a distinction in a research Masters degree in a relevant discipline (e.g. Immunology, cell biology).

The candidate should have:

  • Excellent written and verbal English;
  • The proven ability to work both independently and as part of a team;
  • Honours I (or equivalent) and/or Masters with outstanding thesis grade or Coursework Masters with outstanding performance, particularly in research related courses.
  • Demonstrated outstanding academic achievement as evidenced by high CGPA, rank within class, academic prizes and awards
  • Strong wet lab skills (e.g. cell cultures, assays such as ELISA, ELISPOT). Experience in flow cytometry and/or with mouse handling would be advantageous
  • A candidate will perform animal work, prior experience advantageous but not essential.



I you are interested, please send your CV and cover letter to [email protected]



1.            Horowitz, A., et al., Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med, 2013. 5(208): p. 208ra145.

2.            O'Keeffe, M., W.H. Mok, and K.J. Radford, Human dendritic cell subsets and function in health and disease. Cell Mol Life Sci, 2015. 72(22): p. 4309-25.

3.            Pearson, F.E., et al., Activation of human CD141(+) and CD1c(+) dendritic cells in vivo with combined TLR3 and TLR7/8 ligation. Immunol Cell Biol, 2018. 96(4): p. 390-400.

4.            Ding, Y., et al., FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo. J Immunol, 2014. 192(4): p. 1982-9.

5.            Chiang, M.C., et al., Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets. Eur J Immunol, 2016. 46(2): p. 329-39.

6.            Tullett, K.M., et al., Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition. JCI Insight, 2016. 1(7): p. e87102.

7.            Guillerey, C., N.D. Huntington, and M.J. Smyth, Targeting natural killer cells in cancer immunotherapy. Nat Immunol, 2016. 17(9): p. 1025-36.

8.            Guillerey, C., et al., Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice. Blood, 2012. 120(1): p. 90-9.

9.            Stannard, K.A., et al., Human peripheral blood DNAM-1(neg) NK cells are a terminally differentiated subset with limited effector functions. Blood Adv, 2019. 3(11): p. 1681-1694.

10.          Guillerey, C., et al., Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. Oncoimmunology, 2015. 4(9): p. e1027468.


  • O’Brien L., Guillerey, C. and Radford K. J. Can Dendritic Cell Vaccination Prevent Leukemia Relapse? Cancers, 2019, 11(6):875, doi: 10.3390/cancers11060875
  • Guillerey C, Nakamura K, Pichler C.A., Barkauskas D., Krumeich S., Stannard K., Miles K., Harjunpää H., Yu Y., Casey M., Doban A.I., Lazar M., Hartel G., Smith D., Vuckovic S., Teng W.L.M., Bergsagel P.L., Chesi M., Hill G.R., Martinet L., Smyth M.J. Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. JCI Insight, 2019, doi: 10.1172/jci.insight.125932
  • Stannard K, Lemoine S, Waterhouse N, Vari F, Chatenoud L, Gandhi MK, Martinet L., Smyth MJ* and Guillerey C*. Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Advances. 2019 3:1681-1694; doi: https://doi.org/10.1182/bloodadvances.201803067
  • Guillerey C. Roles of cytotoxic and helper innate lymphoid cells in cancer. Mammalian Genome. 2018 Sep 3. doi: 10.1007/s00335-018-9781-4.
  • Guillerey C*, Harjunpää H*, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L and Smyth MJ.TIGIT immune checkpoint blockade restores CD8+ T cell immunity against multiple myeloma. Blood. 2018 Jul 9. pii: blood-2018-01-825265. doi: 10.1182/blood-2018-01-825265.
  • Oberkampf M*, Guillerey C*, Mouriès J*, Rosenbaum P, Fayolle C, Bobard A, Savina A, Ogier-Denis E, Enninga J, Amigorena S, Leclerc C and Dadaglio G. Mitochondrial reactive oxygen species regulate the induction of CD8+ T cells by plasmacytoid dendritic cells, Nature Communications, 2018 Jun 8;9(1):2241. doi: 10.1038/s41467-018-04686-8.​
  • Guillerey C, Huntington, ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nature Immunology, 2016 Aug 19; 17(9):1025-36.
  • Guillerey C, Nakamura K, Vuckovic S, Hill GF and Smyth MJ, Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies, Cellular and Molecular Life Sciences, 2016 Jan 22; 73(8):1569-89.
  • Guillerey C and Smyth MJ; NK cells and Cancer Immunoediting, Current Topics in Microbiology and Immunology, 2016; 395:115-45.
  • Guillerey C*, De Andrade LF*, Vuckovic S, Miles K, Ngiow SF, Yong MCR, Teng MWL, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, S­myth MJ*, Martinet L* Immunosurveillance and therapy of multiple myeloma is CD226-dependent; Journal of Clinical Investigation, 2015 May 1;125(5):2077-89.
  • Guillerey C*, Chow MT*, Miles K, Olver S, Sceneay J, Takeda K, Moller A, S­myth MJ; Toll-Like Receptor 3 regulates NK cell responses to cytokines and controls metastasis;  OncoImmunology, 2015 April 2; 4(9):e1027468.
  • Guillerey C, Mouriès J, Polo G, Doyen N, Law H, Chan S, Kastner P, Leclerc C, Dadaglio G; Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice; Blood; 2012 Jul 5;120(1):90-9.


ORCIDGoogle Scholar